A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

Gynecologic Oncology

Volumn 113, Issue 3, 2009, Pages 327-330

  Gupta, Divya ^a   Owers, Ricky L ^a   Kim, Mimi ^a   Kuo, Dennis Yi Shin ^a   Huang, Gloria S ^a   Shahabi, Shohreh ^a   Goldberg, Gary L ^a   Einstein, Mark H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Clinical trial; Docetaxel; Ovarian cancer; Topotecan; Uterine cancer

Indexed keywords

DOCETAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOATING; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEG PAIN; LEG SWELLING; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERUS CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TOPOTECAN; UTERINE NEOPLASMS;

EID: 67349180185     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.018     Document Type: Article

References (45)

1. Wadler S., Levy D., Lincoln S., Soori G., Schink J., and Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J. Clin. Oncol. 21 (2003) 2110-2114
2. Miller D., Blessing J., Lent S., and Waggone S. A phase I/II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Proc. Am. Soc. Clin. Oncol. 2468a (2001)
3. Finkler N., and Holloway R. A phase I/II trial of weekly topotecan in the treatment of advanced recurrent metastatic endometrial cancer. Proc. Am. Soc. Clin. Oncol. 2504a (2002)
4. Chambers J., Rutherford T., Schwartz P., Carcangiu M., and Chambers S. A pilot study of topotecan for the treatment of serous endometrial cancer. Proc. Am. Soc. Clin. Oncol. 872a (2001)
5. Traina T.A., Sabbatini P., Aghajanian C., and Dupont J. Weekly topotecan for recurrent endometrial cancer: a case series and review of literature. Gynecol. Oncol. 95 (2004) 235-241
6. Lissoni A., Zanetta G., Losa G., Gabriele A., Parma G., and Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann. Oncol. 7 (1996) 861-863
7. Ball H., Blessing J., Lentz S., and Mutch D. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Ocology Group study. Gynecol. Oncol. 62 (1996) 278-281
8. Rantanen V., Grenman S., Kulmala J., and Grenman R. Endometrial cancer cell lines are sensitive to paclitaxel. Anticancer. Res. 16 (1996) 475-479
9. Gunthert A.R., Ackerman S., Beckmann A.W., Camara O., Kiesel L., et al. Phase II study of weekly docetaxel with recurrent or metastatic endometrial cancer: AGO-uterus 4. Gynecol. Oncol. 104 (2007) 86-90
10. Hirai Y., Hasumi K., Onose R., Kuramoto H., Kuzuya K., et al. Phase II trial of 3-hour infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecol. Oncol. 94 (2004) 471-476
11. Katsumata N., Noda K., Nozawa S., Kitagawa R., Nishimura R., et al. Phase II trial of docetaxel in advanced or recurrent endometrial cancer: a Japanese Cooperative Study. British J. Cancer 93 (2005) 999-1004
12. Scudder S.A., Liu P.Y., Wilczynski S.P., Smith H.O., Jiang C., Hallum III A.V., et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol. Oncol. 96 (2005) 610-615
13. Secord A.A., Havrilesky L.J., Carney M.E., Soper J.T., Clarke-Pearson D.L., Rodriguez G.C., et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int. J. Clin. Onc. 12 (2007) 31-36
14. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. JNCI 96 (2004) 1682-1691
15. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 1062-1067
16. Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 686-690
17. Spannuth W.A., Leath III C.A., Huh W.K., Barnes III M.N., Davidson S.A., et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second line therapy. Gynecol. Oncol. 104 (2007) 591-595
18. Morris R.T. Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol. 90 (2003) S34-S38
19. Kavanagh J.J., Kudelka A.P., de Leon C.G., Tresukosol D., Hord M., Finnegan M.B., et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. 2 (1996) 837-842
20. Francis P., Schneider J., Hann L., Balmaceda C., Barakat R., Phillips M., et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 12 (1994) 2301-2308
21. Katsumata N., Tsunematsu R., Tanaka K., Terashima Y., Ogita S., et al. Phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese Cooperative study. Annals Oncol. 11 (2000) 1531-1536
22. Birkenblit A., Seiden M.V., Matulonis U.A., Penson R.T., Krasner C.N., Roche M., et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol. Oncol. 95 (2004) 624-631
23. Rose P.G., Blessing J.A., Ball H.G., Hoffman J., Warshal D., DeGeest K., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 130-135
24. Tinker A.V., Gebski V., Fitzharris B., Bucks M., Stuart-Harris R., et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel. Gynecol. Oncol. 104 (2007) 647-653
25. Lu C., Shin D., and Jung M. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 19 (2000) 523a
26. Aijaz A., Patel D., Puccio C., et al. A pilot trial of docetaxel, topotecan, and filgastim (G-CSF) in patients (PTS) with recurrent epithelial cancer of the ovary and peritoneum. Proc. Am. Soc. Clin. Oncol. 19 (2000) 407a
27. Zamboni W.C., Egorin M.J., Van Echo D.A., Day R.S., Meisenberg B.R., et al. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J. Clin. Oncol. 18 (2000) 3288-3294
28. Tkaczuk K.H., Zamboni W.C., Tait N.S., Meisenberg B.R., Austin Doyle L., et al. Phase I study of docetaxel and topotecan in patients with solid tumors. Cancer Chemother. Pharmacol. 46 (2000) 228-442
29. Tsao A.S., Shin D.M., Palmer J.L., Lee J.S., and Glisson B.S. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 100 (2004) 2240-2245
30. Dubey S., Hutson P., Alberti D., Arzoomanian R., Binger K., et al. Phase I study of docetaxel and topotecan in patients with advanced malignancies. J. Oncol. Pharm. Pract. 11 (2005) 131-138
31. Posey J.A., Wang H., Hamilton J.E., Delgrosso A., Zhang R., et al. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother. Pharmacol. 56 (2005) 182-188
32. Liu J., and Matulonis U. Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. JNCCN 4 (2006) 947-953
33. Fiorelli J.L., Herzog T.J., and Wright J.D. Current treatment strategies for endometrial cancer. Expert Rev. Anticancer Ther. 8 (2008) 1149-1157
34. Rustin G.J.S., Quinn M., Thigpen T., et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst. 96 (2004) 487-488
35. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
36. Therasse P, Arbuck SJ, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNCI 2000, 92:205-216.
37. The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
38. Abushahin F., Singh D.K., Lurain J.R., Grendys E.C., Rademaker A.W., et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gyencol. Oncol. 108 (2008) 53-57
39. O'Malley D.M., Azodi M., Makkencherry A., McAlpine J., Kelly M., et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian cancer. Gynecol. Oncol. 98 (2005) 242-248
40. Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 686-690
41. Safra T., Menczer J., Bernstein R., Shpigel S., Inbar M.J., et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol. Oncol. 105 (2007) 205-210
42. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., et al. Recurrent ovarian cancer: randomized phase vs topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
43. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. JNCI 86 (1994) 1517-1524
44. Jonsson E., Fridborg H., Nygren P., and Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur. J. Clin. Pharmacol. 54 (1998) 501-514
45. Taron M., Plasencia C., Abad A., Martin C., and Guillot M. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest. New Drugs 18 (2000) 139-147